Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Reply to thread

Message

I have thought about this for sometime, given the recent remote situation we are in. The answer in the short term is YES. Long term is another question. I’m not sure when Januvia goes generic, but its at least 18 months. Therefore, Merck can keep 1 Rep per territory until either Vericiguat or Gefapixant are reviewed internally or the FDA. If either one of these medicines make it to market then I think being 1 up in Chronic Care will be the perfect number. Now if they don’t make it to market then all bets are off. I know in our Region there are lots of Reps who are multiple VP winners and Hall of Famers. I am going to guess they make between $100-120 a year. That is another situation that must be factored into Management's decisions in the future.

[QUOTE="anonymous, post: 6412591"] I have thought about this for sometime, given the recent remote situation we are in. The answer in the short term is YES. Long term is another question. I’m not sure when Januvia goes generic, but its at least 18 months. Therefore, Merck can keep 1 Rep per territory until either Vericiguat or Gefapixant are reviewed internally or the FDA. If either one of these medicines make it to market then I think being 1 up in Chronic Care will be the perfect number. Now if they don’t make it to market then all bets are off. I know in our Region there are lots of Reps who are multiple VP winners and Hall of Famers. I am going to guess they make between $100-120 a year. That is another situation that must be factored into Management's decisions in the future. [/QUOTE]

Name

Verification

Top Bottom

Back